Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITRAS: 68GaNOTA-Anti-MMR-VHH2 PET Imaging in Various Diseases
NCT04758650Phase 2Terminated
- Sponsor
- UZ Brussel
- Start
- Jan 2021
- Primary completion
- Jan 2025
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-NOTA-anti-MMR VHH2 in cancer, carotid artery stenosis, atherosclerosis, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by UZ Brussel. Started Jan 2021; status: terminated.
02
Drugs
68Ga-NOTA-anti-MMR VHH2
03
Conditions
cancercarotid artery stenosisatherosclerosisHodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04758650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758650.